FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ola Dahl

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Ove Talsnes; Ola E Dahl; Fredrik Hjelmstedt; Are Hugo Pripp; Olav Reikerås
Biochemical lung, liver and kidney markers and early death among elderly following hip fracture.
Bengt I Eriksson; Stefan Hantel; Andreas Clemens; Ola E Dahl; Nadia Rosencher; Andreas A Kurth
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Bengt I Eriksson; Martin Feuring; Richard J Friedman; Stefan Hantel; Andreas Clemens; Ola E Dahl; Herbert Noack; Michael Huo
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ola Dahl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Ove Talsnes; Ola E Dahl; Fredrik Hjelmstedt; Are Hugo Pripp; Olav Reikerås
Biochemical lung, liver and kidney markers and early death among elderly following hip fracture.
Archives of orthopaedic and trauma surgery 2012;132(12):1753-8.
2012: Bengt I Eriksson; Stefan Hantel; Andreas Clemens; Ola E Dahl; Nadia Rosencher; Andreas A Kurth
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Thrombosis research 2012;130(6):871-6.
2012: Bengt I Eriksson; Martin Feuring; Richard J Friedman; Stefan Hantel; Andreas Clemens; Ola E Dahl; Herbert Noack; Michael Huo
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Thrombosis research 2012;130(5):818-20.
2012: Ola E Dahl
Bleeding definitions in orthopaedic VTE prophylaxis trials: a real need for standardization.
Thrombosis research 2012;130 Suppl 1():S32.
2012: Pål O Borgen; Ola E Dahl; Olav Reikerås
Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.
Clinical orthopaedics and related research 2012;470(9):2591-8.
2012: Bengt I Eriksson; Richard J Friedman; Martin Homering; Nadia Rosencher; Ola E Dahl
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Thrombosis research 2012;130(2):147-51.
2012: Ola E Dahl; Olivier Borens; Enzo Meani; Nadia Rosencher; Jose Stuyck
What treatment for periprosthetic shoulder infection? Results from a multicentre retrospective series.
International orthopaedics 2012;36(5):1011-7.
2012: Ola E Dahl; Andreas A Kurth; Herbert Noack; Nadia Rosencher; Andreas Clemens; Bengt I Eriksson
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
International orthopaedics 2012;36(4):741-8.
2012: Yngve Falck-Ytter; Charles W Francis; Norman A Johanson; Thomas L Ortel; Stephen G Pauker; Sam Schulman; Clifford W Colwell; Catherine Curley; Ola E Dahl
Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest 2012;141(2 Suppl):e278S-325S.
2012: Ola E Dahl
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
Vascular health and risk management 2012;8():45-57.
2011: Ove Talsnes; Fredrik Hjelmstedt; Ola E Dahl; Are Hugo Pripp; Olav Reikerås
Clinical and biochemical prediction of early fatal outcome following hip fracture in the elderly.
International orthopaedics 2011;35(6):903-7.
2011: Bengt I Eriksson; Ola E Dahl; Michael H Huo; Andreas A Kurth; Stefan Hantel; Karin Hermansson; Janet M Schnee; Richard J Friedman
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Thrombosis and haemostasis 2011;105(4):721-9.
2010: Menno V Huisman; Daniel J Quinlan; Ola E Dahl; Sam Schulman
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Circulation. Cardiovascular quality and outcomes 2010;3(6):652-60.
2010: Pål O Borgen; Ola E Dahl; Olav Reikeras
Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA.
Hip international : the journal of clinical and experimental research on hip pathology and therapy 2010;20(3):301-7.
2010: Ola E Dahl; Menno V Huisman
Dabigatran etexilate: advances in anticoagulation therapy.
Expert review of cardiovascular therapy 2010;8(6):771-4.
2009: Ola E Dahl
Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15 Suppl 1():17S-24S.
2008: Wolfgang Mueck; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Eva Muelhofer; Frank Misselwitz; Bengt I Eriksson
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thrombosis and haemostasis 2008;100(3):453-61.
2008: Ajay K Kakkar; Benjamin Brenner; Ola E Dahl; Bengt I Eriksson; Patrick Mouret; Jim Muntz; Andrea G Soglian; Akos F Pap; Frank Misselwitz; Sylvia Haas
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Lancet 2008;372(9632):31-9.
2008: Bengt I Eriksson; Ola E Dahl; Michael R Lassen; D P Ward; R Rothlein; G Davis; A G G Turpie
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study.
Journal of thrombosis and haemostasis : JTH 2008;6(3):457-63.
2008: Ola E Dahl; Lars C Borris; D Bergqvist; M Schnack Rasmussen; Bengt I Eriksson; A K Kakkar; C W Colwell; Joseph A Caprini; J Fletcher; R J Friedman; Michael R Lassen; Simon P Frostick; M Sakon; L M Kwong; V V Kakkar
Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use.
International angiology : a journal of the International Union of Angiology 2008;27(1):60-7.
2008: D Warwick; Ola E Dahl; W D Fisher
Orthopaedic thromboprophylaxis: limitations of current guidelines.
The Journal of bone and joint surgery. British volume 2008;90(2):127-32.
2008: Wolfgang Mueck; Bengt I Eriksson; Kenneth A Bauer; Lars Borris; Ola E Dahl; William D Fisher; Michael Gent; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Clinical pharmacokinetics 2008;47(3):203-16.
2007: Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; A A Kurth; C Niek van Dijk; Simon P Frostick; Peter Kälebo; A V Christiansen; S Hantel; Rohan Hettiarachchi; J Schnee; Harry R Büller
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Journal of thrombosis and haemostasis : JTH 2007;5(11):2178-85.
2007: Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; Andreas A Kurth; C Niek van Dijk; Simon P Frostick; Martin H Prins; Rohan Hettiarachchi; Stefan Hantel; Janet Schnee; Harry R Büller
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Lancet 2007;370(9591):949-56.
2007: Daniel J Quinlan; J W Eikelboom; Ola E Dahl; Bengt I Eriksson; Paul S Sidhu; J Hirsh
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.
Journal of thrombosis and haemostasis : JTH 2007;5(7):1438-43.
2007: William D Fisher; Bengt I Eriksson; Kenneth A Bauer; Lars C Borris; Ola E Dahl; Michael Gent; Sylvia Haas; Martin Homering; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Louis M Kwong; Frank Misselwitz; Alexander G G Turpie
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Thrombosis and haemostasis 2007;97(6):931-7.
2007: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Frank Misselwitz; Eva Muehlhofer; Peter Kälebo
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Thrombosis research 2007;120(5):685-93.
2006: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Eva Muehlhofer; Christoph Dierig; Frank Misselwitz; Peter Kälebo
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Circulation 2006;114(22):2374-81.
2006: Bård T Bjørnarå; Tor Erik Gudmundsen; Ola E Dahl
Frequency and timing of clinical venous thromboembolism after major joint surgery.
The Journal of bone and joint surgery. British volume 2006;88(3):386-91.
2006: Ola E Dahl; Mats Ogren; Giancarlo Agnelli; Bengt I Eriksson; Alexander T Cohen; Patrick Mouret; Nadia Rosencher; Anders Bylock; Seva Panfilov; Magnus Andersson
Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty.
Pathophysiology of haemostasis and thrombosis 2006;35(6):428-34.
2006: Meyer M Samama; Ola E Dahl; Patrick Mismetti; Daniel J Quinlan; Nadia Rosencher; Marleen Cornelis; Han de Vries; Ineke van Beusekom; James P Kahan
An electronic tool for venous thromboembolism prevention in medical and surgical patients.
Haematologica 2006;91(1):64-70.
2006: Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Frank Misselwitz; Peter Kälebo
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Journal of thrombosis and haemostasis : JTH 2006;4(1):121-8.
2005: Ola E Dahl; Jan Jacques Michiels
Ximelagatran as a new oral anticoagulant for thrombosis.
Seminars in vascular medicine 2005;5(3):223-5.
2005: Ola E Dahl; Joseph A Caprini; Clifford W Colwell; Simon P Frostick; Sylvia Haas; Russell D Hull; Sylvie Laporte; Paul D Stein
Fatal vascular outcomes following major orthopedic surgery.
Thrombosis and haemostasis 2005;93(5):860-6.
2005: Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.
Journal of clinical pharmacology 2005;45(5):555-63.
2005: Ola E Dahl; Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Patrick Mouret; Nadia Rosencher; Seva Panfilov; Anders Bylock; Magnus Andersson
Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery : Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety.
Clinical drug investigation 2005;25(1):65-77.
2005: Bengt I Eriksson; Ola E Dahl; Harry R Büller; Rohan Hettiarachchi; Nadia Rosencher; M-L Bravo; Lennart Ahnfelt; Franco Piovella; Joachim Stangier; Peter Kälebo; P Reilly
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Journal of thrombosis and haemostasis : JTH 2005;3(1):103-11.
2004: Ola E Dahl
Divergent regional opinions on thromboembolic complications and prophylaxis among surgeons.
Journal of thrombosis and haemostasis : JTH 2004;2(11):1899-900.
2004: Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Peter Kälebo; Joachim Stangier; Gerhard Nehmiz; K Hermansson; V Kohlbrenner
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Journal of thrombosis and haemostasis : JTH 2004;2(9):1573-80.
2004: Ola E Dahl
Orthopaedic surgery as a model for drug development in thrombosis.
Drugs 2004;64 Suppl 1():17-25.
2004: Bengt I Eriksson; Ola E Dahl
Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
Drugs 2004;64(6):577-95.
2003: Meyer M Samama; Ola E Dahl; Daniel J Quinlan; Patrick Mismetti; Nadia Rosencher
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.
Haematologica 2003;88(12):1410-21.
2003: Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Michael R Lassen; Patrick Mouret; Nadia Rosencher; Peter Kälebo; Seva Panfilov; Christina Eskilson; Magnus Andersson; A Freij
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Journal of thrombosis and haemostasis : JTH 2003;1(12):2490-6.
2003: Ola E Dahl; Tor Erik Gudmundsen; Bård T Bjørnarå; Dag M Solheim
Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients.
Acta orthopaedica Scandinavica 2003;74(3):299-304.
2003: Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Patrick Mouret; Nadia Rosencher; Christina Eskilson; Ingela Nylander; Lars Frison; Mats Ogren
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Thrombosis and haemostasis 2003;89(2):288-96.
2002: Bengt I Eriksson; David Bergqvist; Peter Kälebo; Ola E Dahl; Siv Lindbratt; Anders Bylock; Lars Frison; Ulf G Eriksson; Lennart Welin; David Gustafsson
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Lancet 2002;360(9344):1441-7.
2002: Ola E Dahl; David Bergqvist
Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery.
Current opinion in pulmonary medicine 2002;8(5):394-7.
2001: Ola E Dahl; D Bergqvist; A T Cohen; Simon P Frostick; R D Hull
Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
Acta orthopaedica Scandinavica 2001;72(2):199-204.
2000: Ola E Dahl; Tor Erik Gudmundsen; L Haukeland
Late occurring clinical deep vein thrombosis in joint-operated patients.
Acta orthopaedica Scandinavica 2000;71(1):47-50.
1999: Ola E Dahl; Simon P Frostick; R D Hull
Thromboembolism--an academic concern or a clinical reality?
Acta orthopaedica Scandinavica 1999;70(4):404-6.